Therapeutic effect of human recombinant interferon-alpha-2C in essential thrombocythaemia.
Human recombinant interferon-alpha 2C was given to 4 patients with essential thrombocythaemia. Three patients achieved a complete remission on day 19 +/- 1 and the 4th achieved a partial remission. After 4 weeks of induction therapy, a maintenance therapy of twice weekly intramuscular injections of 5 X 10(6) or 10 X 10(6) IU was instituted but did not maintain the remission.
D000368:Aged; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D011994:Recombinant Proteins / Q000627:therapeutic use*; D013920:Thrombocythemia, Essential / Q000628:therapy*
D007370:Interferon Type I; D011994:Recombinant Proteins